
Pfizer’s coronavirus vaccine shows moderate side-effects in clinical study
pharmafile | September 16, 2020 | News story | Research and Development | COVID-19, Pfizer, Pfizer vaccine, coronavirus vaccine
Pfizer has said that participants in a late-stage trial for its COVID-19 vaccine candidate have shown mild to moderate side effects.
The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with BioNTech. Over 12,000 study participants have received a second dose of the vaccine.
Unlike the AstraZeneca study which was forced to come to a halt recently, the Pfizer trial is not being paused as the symptoms shown are not severe or life-threatening.
Fatigue was the most common side-effect, but researchers do not yet know how much of the affected had received the vaccine or a placebo; 36% of the 18 to 64 age group and 27% of the 65 to 84 group reported this symptom. After fatigue, the most common reported side-effects were headaches, muscle pain, joint pain and chills.
In a company call, Dr Kathrin Janson, the Head of Research at Pfizer, said that researchers would “notify us if they had any safety concerns and have not done that to date.”
Conor Kavanagh
Related Content

COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …

Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …

FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …






